NASDAQ:INGNInogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INGN shares have decreased by 21.3% and is now trading at $31.98.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) issued its earnings results on Tuesday, August, 4th. The medical technology company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.20. The medical technology company earned $71.70 million during the quarter, compared to the consensus estimate of $79.96 million. Inogen had a return on equity of 2.68% and a net margin of 1.96%. The company's revenue was down 29.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 earnings per share.
View Inogen's earnings history.

4 equities research analysts have issued 12-month price objectives for Inogen's shares. Their forecasts range from $35.00 to $75.00. On average, they expect Inogen's stock price to reach $51.67 in the next year. This suggests a possible upside of 61.6% from the stock's current price.
View analysts' price targets for Inogen.

Media headlines about INGN stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Inogen earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the medical technology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about Inogen.

Some companies that are related to Inogen include Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Ocugen (OCGN), Allied Healthcare Products (AHPI), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Bionik Laboratories (BNKL) and NanoVibronix (NAOV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Netflix (NFLX), First Solar (FSLR) and Intel (INTC).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (1.19%), Principal Financial Group Inc. (0.64%), Assenagon Asset Management S.A. (0.37%), Hussman Strategic Advisors Inc. (0.23%), Swiss National Bank (0.19%) and UBS Group AG (0.18%). Company insiders that own Inogen stock include Brenton Taylor, Heath Lukatch, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Beacon Investment Advisory Services Inc., Russell Investments Group Ltd., Chicago Capital LLC, Riverbridge Partners LLC, Texas Permanent School Fund, PNC Financial Services Group Inc., and Cardinal Capital Management.
View insider buying and selling activity for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hussman Strategic Advisors Inc., UBS Group AG, WINTON GROUP Ltd, Exchange Traded Concepts LLC, Teza Capital Management LLC, Swiss National Bank, and Envestnet Asset Management Inc.. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $31.98.

Inogen has a market capitalization of $705.67 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

The official website for Inogen is www.inogen.com.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]